Howerton E, Dahlin K, Edholm CJ, Fox L, Reynolds M, Hollingsworth B, Lytle G, Walker M, Blackwood J, Lenhart S. The effect of governance structures on optimal control of two-patch epidemic models. J Math Biol. 2023 Oct 20;87(5):74. doi: 10.1007/s00285-023-02001-8
Offen W, Chuang-Stein C, Dmitrienko A, Copley-Merriman K. Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the PhRMA. Drug Inf J. 2007;4:31-46.
Westfall PH, Prillaman B, Ho SY. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat. 2001;11(3):125-38. doi: 10.1081/BIP-100107653
Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. Drug Inf J. 2000;34(4):1273-91.
Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes. Drug Inf J. 1994 Jan 1;28(1):19-25.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.